SLC5A1 and Hypoglycemia: However, dual SGLT1/2 inhibition may increase the risk of hypoglycemia, and the stronger diuretic effect could expose patients to hypotension, pre-renal failure, haemoconcentration-related complications, and diabetic ketoacidosis [11].